{"task_id": "83531efdb69d3def", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 230/464)", "text": "t\nMANAGEMENT (CONT\u2019D)\nCancer of Unknown Origin\n219\n\n--- Page 241 ---\nMANAGEMENT (CONT\u2019D)\nPresentation\nLikely primary\nKey history and physical Investigations\nEmpiric treatment(s)\nSquamous cell\ncarcinoma with\ninguinal\nlymphadenopathy\nCervical/rectal cancer\nPelvic exam, colposcopy\nAnoscopy,\nsigmoidoscopy, CT\nabd/pelvis\nLymph node dissection,\nchemoradiation\nPeritoneal\ncarcinomatosis\nOvarian cancer variant,\nprimary peritoneal\ncancer, metastasis from\ncolorectal or stomach\ncancer\nPelvic exam\nColonoscopy,\ngastroscopy, CT abd/\npelvis, CEA, CA-125\n(ratio 1/20)\nTreated as ovarian with\ncarboplatin, paclitaxel\nLiver metastasis\nGI (colorectal [usually\notherwise well],\npancreatic, esophageal,\ngastric, hepatic\n[orientals or cirrhosis],\nlung, breast\nGeneral\nCEA, CA 19-9, CA 15-3,\nAFP, colonoscopy\nGemcitabine, pemetrexed\nLung nodule(s)\nMetastasis (lower lobes,\nmultiple), lung cancer\n(upper lobe, single)\nSmoking history\nCT chest\nPlatinum-based doublet\nchemotherapy\nMalignant pleural\neffusion\nLung adenocarcinoma,\nmesothelioma\nSmoking, asbestos\nexposure\nThoracentesis\nThoracentesis\nBlastic bone\nmetastasis\nProstate (most common),\nlung, breast\nDRE\nPSA, plain X-rays of\nbones, bone scan\nHormonal therapy if suspect\nprostate cancer\nTumor Markers\nPATHOPHYSIOLOGY\nDEFINITION\nsubstances that can be measured quan\ntitatively in the serum in order to detect a cancer and its\norgan of origin. May act as surrogate of tumor bulk\nTYPES OF TUMOR MARKERS\n\u0002\nTUMOR-SPECIFIC PROTEINS\nfusion gene product in\nCML (bcr abl), monoclonal band in multiple myeloma\n\u0002\nONCOFETAL\nANTIGENS\n(non specific)\nexpressed\nduring embryological development and in cancer\ncells. Examples include CEA in all GI and some\nother tumors, AFP in hepatocellular carcinoma\nand germ cell tumor, and CA 125 in ovarian cancer\n\u0002\nOVER-EXPRESSED PROTEINS (non specific)\npresent\nin normal differentiated cells but lesser amount.\nExamples include PSA in prostate cancer and CA\n15 3 in breast cancer\nUTILITY OF TUMOR MARKERS\nscreening, diagno\nsis, prognosis, monitor response to treatment, moni\ntor recurrence (after adjuvant therapy)\nPROSTATE SPECIFIC ANTIGEN (PSA)\nNORMAL\nRANGE\n<4\nng/mL\n(age dependent\nrange: 40 49 years old <2.5 ng/mL, 50 59 years\nold <3.5 ng/mL, 60 69 years old <4.5 ng/mL,\n70 79 years old <6.5 ng/mL)\nELEVATED\nprostate cancer, BPH, prostatitis, peri\nneal trauma\nPROSTATE SPECIFIC ANTIGEN (PSA) (CONT\u2019D)\nUTILITY IN PROSTATE CANCER\n\u0002\nSCREENING\nstart at age 50 for men with life expec\ntancy >10 years. Perform PSA annually if PSA\n>1 ng/mL, and every 4 years if PSA <1 ng/mL.\nCombine with annual DRE\n\u0002\nDIAGNOSIS, PROGNOSIS, RESPONSE, FOLLOW-UP FOR\nRELAPSE\nextremely useful. See PROSTATE CAN\nCER for more details (p. 210)\nCARCINOEMBRYONIC ANTIGEN (CEA)\nNORMAL RANGE\n<4 mg/L (<5 mg/L for smokers)\nELEVATED\ncolorectal cancer (sens <25% in early\ncancer and 75% in advanced cancer), gastric cancer\n(sens 50%), pancreatic cancer (sens 50%), breast can\ncer (sens 40 73%), lung cancer (sens 77%), ovarian\ncancer, IBD (4 10 mg/L), cirrhosis, hepatitis, pancrea\ntitis, peptic ulcer disease, smoking (sens 19%),\nchronic\nlung\ndisease,\nhypothyroidism,\nnormal\n(sens 3%)\nUTILITY IN COLORECTAL CANCER\n\u0002\nPROGNOSIS\nCEA >5 mg/L may correlate with\npoorer prognosis\n\u0002\nADJUVANT SETTING\nelevated postoperative CEA\nimplies the presence of persistent disease and\nrequires further evaluation. For stage II and III\ndisease post resection, CEA levels should be per\nformed every 3 months for at least 3 years if the\n220\nTumor Markers", "text_length": 3462, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 230/464)", "type": "chunk", "chunk_index": 229, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.563331", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.564372", "status": "complete", "chunks_added": 2}